Original language | English |
---|---|
Pages (from-to) | 1403-1407 |
Number of pages | 5 |
Journal | Leukemia |
Volume | 27 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2013 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Leukemia, Vol. 27, No. 6, 06.2013, p. 1403-1407.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia
T2 - A phase i study
AU - Platzbecker, U.
AU - Braulke, F.
AU - Kündgen, A.
AU - Götze, K.
AU - Bug, G.
AU - Schönefeldt, C.
AU - Shirneshan, K.
AU - Röllig, C.
AU - Bornhäuser, M.
AU - Naumann, R.
AU - Neesen, J.
AU - Giagounidis, A.
AU - Hofmann, W. K.
AU - Ehninger, G.
AU - Germing, U.
AU - Haase, D.
AU - Wermke, M.
N1 - Funding Information: We thank the investigators of the Groupe Francophone des Myélodysplasies and Groupe Ouest-Est d’étude des Leucémies Aiguës et Autres Maladies du Sang for including patients, and M Bourmaud for technical assistance. This study was supported by grant no. 109686 from the Deutsche Krebshilfe awarded to FD and grants from the Program Hospitalier de Recherche Clinique (MDS-04 to MF and MYELOMONO to ES), Association Laurette Fugain (to ND), Ligue Nationale Contre le Cancer (to OAB and to ES) and INCa translational research grants (to MF, and to ES). Funding Information: U Platzbecker, U Germing and D Haase have received honoraria and research funding from Celgene Corporation. A Kündgen, K Götze, M Bornhäuser, A Giagounidis and W-K. Hofmann have received honoraria from Celgene Corporation. The remaining authors declare no conflict of interest.
PY - 2013/6
Y1 - 2013/6
UR - http://www.scopus.com/inward/record.url?scp=84878910291&partnerID=8YFLogxK
U2 - 10.1038/leu.2013.26
DO - 10.1038/leu.2013.26
M3 - Letter
C2 - 23354011
AN - SCOPUS:84878910291
SN - 0887-6924
VL - 27
SP - 1403
EP - 1407
JO - Leukemia
JF - Leukemia
IS - 6
ER -